Peptide · Fact sheet
Ipamorelin
Also known as ipamorelin acetate
Ipamorelin is an experimental peptide that can stimulate growth-hormone release. It is not an FDA-approved medicine, and FDA has described important evidence gaps and potential safety concerns.
What is Ipamorelin?
Ipamorelin is a synthetic growth hormone secretagogue that acts at the ghrelin receptor.
It has been investigated in human research, including studies of gastrointestinal motility, but that does not establish common online claims.
Benefits & claims
It is promoted for muscle, recovery, sleep, fat loss, and anti-aging, often in combination with CJC-1295.
Combination marketing makes it harder to know which ingredient caused an effect or adverse event.
What the evidence supports
- Studies confirm pharmacologic effects on hormone signaling.
- Evidence does not yet establish a favorable benefit-risk profile for popular consumer uses.
Research areas
- Growth hormone release
- Gastrointestinal motility
- Postoperative ileus
- Growth-hormone and gastrointestinal pathway effects
Dosage & frequency
Human study contextThe verified early human study used a single intravenous infusion to characterize hormone responses. It does not establish a subcutaneous wellness or recovery regimen.
Healthy-volunteer PK/PD study
Healthy male volunteers in ascending-dose cohorts
- Amount
- 4.21–140.45 nmol/kg across separate cohorts
- Frequency
- One 15-minute study infusion
- Route studied or labeled
- Intravenous
Pharmacokinetic and GH-response study; not a repeated subcutaneous regimen.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Terminal half-life in the IV study
- Approximately two hours; route-specific research estimate.
Formulation differences
- Research with a pharmaceutical study formulation cannot establish equivalence for other preparations.
Interactions & precautions
- A single IV PK/PD experiment does not establish interactions during repeated subcutaneous use or with other endocrine treatments.
What is still unresolved
- Clinical efficacy and a supported repeated-use subcutaneous schedule remain unestablished.
Side effects & risks
- FDA describes potential immune reactions and complexities related to impurities and peptide characterization.
- FDA notes serious adverse events, including deaths, in a study using intravenous ipamorelin for gastric motility; that context does not establish cause for every event but is a serious signal.
- Safety information for other routes and long-term use is insufficient.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Early human evidenceHuman studies exist, but they do not provide strong evidence for the broad performance, recovery, or anti-aging outcomes promoted to consumers.
Studies
Registry record for an ipamorelin postoperative ileus study.
Human pharmacology study characterizing ipamorelin exposure and growth-hormone responses.
Randomized proof-of-concept study of ipamorelin for postoperative ileus.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 3 sourced accounts by reported effect.
Energy: reported experiences
Better energy and recovery with CJC-1295
A commenter described better energy, sleep, mood, concentration and gym recovery during combined ipamorelin and CJC-1295 use.
Reported use in this account
- Product
- Ipamorelin with CJC-1295
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Two reported three-month exposure periods
Other exposures described: CJC-1295
Neither the products nor outcomes were independently checked. The combination and ongoing training prevent isolating ipamorelin.
Read the original accountEasier sleep with daytime sleepiness and vivid dreams
A person using products labeled ipamorelin and CJC-1295 without DAC reported falling asleep easily, vivid dreams, lower motivation and unwanted daytime sleepiness.
Reported use in this account
- Product
- Ipamorelin with CJC-1295 described as without DAC
- Amount
- 200 mcg of ipamorelin
- Frequency
- On five days per week; administrations per day not stated
- Route
- Injection; specific route not stated
- Duration
- Three weeks stated; another week number conflicts
Other exposures described: CJC-1295 described as without DAC
Combined exposure prevents attribution to ipamorelin. The accompanying product was labeled CJC-1295 without DAC, not the long-acting CJC-1295 studied in the cited clinical research.
Read the sleepiness reportSleep: reported experiences
Better energy and recovery with CJC-1295
A commenter described better energy, sleep, mood, concentration and gym recovery during combined ipamorelin and CJC-1295 use.
Reported use in this account
- Product
- Ipamorelin with CJC-1295
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Two reported three-month exposure periods
Other exposures described: CJC-1295
Neither the products nor outcomes were independently checked. The combination and ongoing training prevent isolating ipamorelin.
Read the original accountEasier sleep with daytime sleepiness and vivid dreams
A person using products labeled ipamorelin and CJC-1295 without DAC reported falling asleep easily, vivid dreams, lower motivation and unwanted daytime sleepiness.
Reported use in this account
- Product
- Ipamorelin with CJC-1295 described as without DAC
- Amount
- 200 mcg of ipamorelin
- Frequency
- On five days per week; administrations per day not stated
- Route
- Injection; specific route not stated
- Duration
- Three weeks stated; another week number conflicts
Other exposures described: CJC-1295 described as without DAC
Combined exposure prevents attribution to ipamorelin. The accompanying product was labeled CJC-1295 without DAC, not the long-acting CJC-1295 studied in the cited clinical research.
Read the sleepiness reportMood: reported experiences
Better energy and recovery with CJC-1295
A commenter described better energy, sleep, mood, concentration and gym recovery during combined ipamorelin and CJC-1295 use.
Reported use in this account
- Product
- Ipamorelin with CJC-1295
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Two reported three-month exposure periods
Other exposures described: CJC-1295
Neither the products nor outcomes were independently checked. The combination and ongoing training prevent isolating ipamorelin.
Read the original accountEasier sleep with daytime sleepiness and vivid dreams
A person using products labeled ipamorelin and CJC-1295 without DAC reported falling asleep easily, vivid dreams, lower motivation and unwanted daytime sleepiness.
Reported use in this account
- Product
- Ipamorelin with CJC-1295 described as without DAC
- Amount
- 200 mcg of ipamorelin
- Frequency
- On five days per week; administrations per day not stated
- Route
- Injection; specific route not stated
- Duration
- Three weeks stated; another week number conflicts
Other exposures described: CJC-1295 described as without DAC
Combined exposure prevents attribution to ipamorelin. The accompanying product was labeled CJC-1295 without DAC, not the long-acting CJC-1295 studied in the cited clinical research.
Read the sleepiness reportFocus: reported experiences
Better energy and recovery with CJC-1295
A commenter described better energy, sleep, mood, concentration and gym recovery during combined ipamorelin and CJC-1295 use.
Reported use in this account
- Product
- Ipamorelin with CJC-1295
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Two reported three-month exposure periods
Other exposures described: CJC-1295
Neither the products nor outcomes were independently checked. The combination and ongoing training prevent isolating ipamorelin.
Read the original accountStrength: reported experiences
Better energy and recovery with CJC-1295
A commenter described better energy, sleep, mood, concentration and gym recovery during combined ipamorelin and CJC-1295 use.
Reported use in this account
- Product
- Ipamorelin with CJC-1295
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Two reported three-month exposure periods
Other exposures described: CJC-1295
Neither the products nor outcomes were independently checked. The combination and ongoing training prevent isolating ipamorelin.
Read the original accountGlucose: reported experiences
A serious low-glucose episode during combined use
An author described an emergency assessment and hospitalization for reactive hypoglycemia while using ipamorelin and tesamorelin.
Reported use in this account
- Product
- Product described as ipamorelin
- Amount
- 500 mcg
- Frequency
- Every morning
- Route
- Not specified clearly
- Duration
- Not specified clearly
Other exposures described: Tesamorelin for about three weeks; Fasted exercise and a change from a low-carbohydrate diet
Exercise and dietary changes were concurrent, records were unavailable, and the author offered remaining products for resale. The cause is unverified.
Read the original accountAcute illness: reported experiences
A serious low-glucose episode during combined use
An author described an emergency assessment and hospitalization for reactive hypoglycemia while using ipamorelin and tesamorelin.
Reported use in this account
- Product
- Product described as ipamorelin
- Amount
- 500 mcg
- Frequency
- Every morning
- Route
- Not specified clearly
- Duration
- Not specified clearly
Other exposures described: Tesamorelin for about three weeks; Fasted exercise and a change from a low-carbohydrate diet
Exercise and dietary changes were concurrent, records were unavailable, and the author offered remaining products for resale. The cause is unverified.
Read the original accountApproval status
Ipamorelin is not FDA approved. FDA has described potential immunogenicity and impurity concerns and insufficient safety information for certain routes.
Mid-stage study completed without approval
Ipamorelin reached a Phase 2 postoperative-ileus study, but it has no FDA-approved product and the cited research does not support broad consumer wellness claims.
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Long-term safety and uncommon adverse effects
- Meaningful benefits for body composition, recovery, sleep, or aging
- Safety of combinations promoted online
- Product identity, purity, and consistency outside approved manufacturing
Summary
Ipamorelin is unapproved and lacks strong human evidence for advertised recovery, muscle or anti-aging benefits.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA: bulk substances that may present significant safety risks
FDA summaries of safety concerns and evidence gaps for selected bulk substances used in compounding.
- clinical trialsClinicalTrials.gov: ipamorelin for postoperative ileus
Registry record for an ipamorelin postoperative ileus study.
- pubmedIpamorelin pharmacokinetic-pharmacodynamic study
Human pharmacology study characterizing ipamorelin exposure and growth-hormone responses.
- pubmedIpamorelin postoperative ileus proof-of-concept study
Randomized proof-of-concept study of ipamorelin for postoperative ileus.